Blog
RSS FeedPosted by Michael Wonder on 15 Dec 2022
Pembrolizumab for the neo-adjuvant and adjuvant treatment of patients with early or locally advanced triple negative breast cancer
14 December 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 15 Dec 2022
Amivantamab for the treatment of patients with EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy
14 December 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 15 Dec 2022
Cabozantinib maleate for patients with previously treated advanced hepatocellular carcinoma
14 December 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 04 Dec 2022
Brexucabtagene autoleucel for the treatment of adults with relapsed or refractory B-cell acute lymphoblastic leukaemia
2 December 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 01 Dec 2022
Cemiplimab for the first-line treatment of patients wth advanced or metastatic PD-L1 positive non-small-cell lung cancer
1 December 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 30 Nov 2022
Ripretinib for the treatment of patients with an advanced gastro-intestinal stromal tumour after three or more therapies
30 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 28 Nov 2022
Bayer’s Nubeqa receives MHRA approval to treat metastatic prostate cancer
28 November 2022 - The treatment will be made available immediately through an early access deal with NHS England. ...
Posted by Michael Wonder on 24 Nov 2022
New life-extending treatment for rare forms of advanced gastro-oesophageal cancer recommended by NICE
24 November 2022 - Around 3,000 people could be eligible for a new life-extending combination therapy to treat rare forms of ...
Posted by Michael Wonder on 22 Nov 2022
Tisagenlecleucel for the treatment of patients with follicular lymphoma after two or more therapies
22 November 2022 - NICE is unable to make a recommendation on the use of tisagenlecleucel for the treatment of adults ...
Posted by Michael Wonder on 17 Nov 2022
Targeted treatment for rare form of aggressive lung cancer gets NICE approval
16 November 2022 - Mobocertinib recommended as a treatment for a rare and aggressive form of lung cancer. ...
Posted by Michael Wonder on 10 Nov 2022
Olaparib for adjuvant treatment of patients with high risk, HER2 negative, BRCA positive early breast cancer after chemotherapy
10 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 08 Nov 2022
NICE final draft guidance adds further treatment option for triple negative breast cancer
8 November 2022 - NICE has today published final draft guidance which recommends pembrolizumab as an option for people with ...
Posted by Michael Wonder on 23 Oct 2022
Could more medicines be recommended for routine commissioning rather than spending time in the Cancer Drugs Fund?
19 October 2022 - A new analysis commissioned by the ABPI suggests they could. ...
Posted by Michael Wonder on 19 Oct 2022
Zanubrutinib for the treatment of patients with Waldenström’s macroglobulinaemia
19 October 2022 - NICE has published evidence-based recommendations on the use of zanubrutinib for the treatment of adults with ...
Posted by Michael Wonder on 19 Oct 2022
Pembrolizumab for adjuvant treatment of adults with renal cell carcinoma
19 October 2022 - NICE has published evidence-based recommendations on the use of pembrolizumab for the adjuvant treatment of adults ...